Update (7 July): THANK YOU for all the kind donation so far. Please contribute what you can. Angi is holding steady, staying positive, and the first treatment will be tomorrow. Send prayers, vibes and join us in solidarity: Expect a Miracle! Love, Martin
The story for donors: Our Dear Friend and Colleagues of Angi Lamb
Last November, 2019, we learned Angi has Stage 4 - small cell lung cancer with liver metastasis. She's had rounds of chemotherapy, and radiotherapy, and has responded among the best seen for such an aggressive cancer.
Now, July 2020:
All NHS resources have been exhausted, and the only hope (a very credible, good hope) is an experimental treatment in Glasgow - "KEYTRUDA (PEMBROLIZUMAB) (N1-KEYTRUDA) " - given by Dr Brian Clark.
We need to start this treatment immediately.
Some have had remarkable results on this new treatment, giving/adding precious years to people's lives.
Without it, the prognosis is only several months.
The treatment is expensive, £12,800 per dose — and while there will be an application for compassionate treatment, we need to get the first two underway.
Doses can either be 400mg every six weeks or 200mg every three. Because I have slightly challenged veins taking the higher dose reduces number of cannulas and risk of infection.
Initial 2 treatments x £12,800 = 25,600
Any contribution is lovingly and gratefully appreciated. This campaign is being managed by Angi's designated powers of attorney in compliance with all legal requirements.
Note: Funding this for Angi is also a contribution to the research, which in the long run, will also help others
Angi's Caring Bridge Site is here:
Long Read - About the treatment:
KEYTRUDA is a type of immunotherapy that works by blocking the PD-1 pathway and to help prevent cancer cells from hiding. KEYTRUDA helps the immune system do what it was meant to do: detect and fight cancer cells.
KEYTRUDA is not chemotherapy or radiation therapy—it is an immunotherapy and it works with your immune system to help fight cancer.
Immunotherapy is still proving itself. It's often used as a last resort, once other therapies have reached the end of their effectiveness.
The USA Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. 18 Jun 2019
So approved in USA but not in EU yet.
DonationsSee top donations
- Andrew Glazer
- Francis Larkins
- Anne-Marie Moore
- Joyce McLean